A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Machine Learning


Pharmaceutical Artificial Intelligence in 2020: The Sector is Heating Up For Investments

   by Andrii Buvailo    294
Pharmaceutical Artificial Intelligence in  2020: The Sector is Heating Up For Investments

Table of Contents: 

  1. Introduction

  2. The abundance of venture capital, major funding rounds 

  3. New AI-driven biotech startups founded in 2020

  4. Notable AI-focused collaborations involving “big pharma” players

  5. AI adoption by the contract research organizations (CROs) 

  6. AI-designed drug candidates in clinical trials 

  7. The emerging role of AI tech in fighting COVID-19

AI-ML Drug Discovery Summit 2021

   by BiopharmaTrend    138
AI-ML Drug Discovery Summit 2021

R&D & Clinical Processes for the Future: Accurate, Efficient & Cost-Effective

The AI-ML: Drug Discovery Summit is the industry’s definitive guide to translating the wealth of tech available to successfully implement a working and practically effective drug discovery and development platform.

Marshall Pillay joins OKRA

   by Marina Gonzalo    175
Marshall Pillay joins OKRA

Cambridge, UK, October 5th 2020 - OKRA is thrilled to announce the appointment of Marshall Pillay as VP Commercial - Europe and International. Starting today, Marshall will join OKRA from AKTANA, where he was most recently GM of Europe, responsible for all business and operations in the continent.

The AI Productivity Game in Pharma

   by Amandeep Singh    826
The AI Productivity Game in Pharma

The pharmaceutical business is one of the riskiest industries to venture into. Drug discovery is an artisanal process where a carefully designed drug takes about 10 years and approximately 2.5 billion dollars to be approved and launched into the market. The complexity of biological systems places the odds at a ridiculous failure rate of 90%. In recent years, the declining efficiency of the R&D efforts has put the pharma industry on its toes. 

In the past decade, Artificial Intelligence (AI) has already revolutionized several industries, including automotive, entertainment and fintech. AI dictates routes and ETA on google maps, executes multiple stock exchange transactions, enables facial recognition, and powers the voice assistants Siri and Alexa. However, the adoption of AI in pharma has been restricted due to limited data available about what works (the successful 10%) and the innate complexity of the process of drug discovery.

OKRA raises ambitious target to 6 million predictions in Life Sciences by end of 2020

   by Marina Gonzalo    140
OKRA raises ambitious target to 6 million predictions in Life Sciences by end of 2020

Cambridge, UK, September 29th 2020 - Following on from June's breakthrough news that OKRA hit its target of 2 million validated predictions at >95% accuracy a full 6 months early, the company has set its sights on a record-breaking 6 million predictions completed by year end. This means that pharma companies have benefitted from an unparalleled level of support during the most uncertain time in recent memory, using predictions to guide their staff to take the right next step. This is 1 million more than the revised target set only in June.